For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid endogenous neuropeptide first isolated in 1974 from the cerebral venous blood of sleeping rabbits by the Schoenenberger-Monnier group in Switzerland. Despite its name suggesting a clear mechanism, DSIP's sleep-promoting effects in humans have been contradictory across 40-plus years of research: some controlled trials showed modest sleep improvements, while the most rigorous study (Schneider-Helmert 1992, n=16, double-blind) concluded that short-term treatment of chronic insomnia was not likely to be of major therapeutic benefit. The compound's most compelling human clinical data are actually in addiction medicine: a 1984 uncontrolled study of n=107 inpatients (n=47 alcohol withdrawal, n=60 opiate withdrawal) reported benefits in 97% of opiate-dependent and 87% of alcohol-dependent patients with IV DSIP. In mouse lifespan studies, a DSIP-containing preparation (Deltaran) extended maximum lifespan by 24.1% and reduced spontaneous tumor incidence 2.6-fold. No receptor or precursor gene for DSIP has been identified in 50 years of research.
The complete DSIP profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use